MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial-Reference-Cited by-同舟云学术

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

Published:2019-08-28 Issue:2 Volume:34 Page:522-532
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Pott Christiane,Sehn Laurie H.,Belada David,Gribben John,Hoster Eva,Kahl Brad,Kehden Britta,Nicolas-Virelizier Emmanuelle,Spielewoy Nathalie,Fingerle-Rowson Guenter,Harbron Chris,Mundt Kirsten,Wassner-Fritsch Elisabeth,Cheson Bruce D.

Funder

F. Hoffmann-La Roche Ltd/Genentech Inc.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0559-9.pdf

Reference29 articles.

1. Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma—novel and emerging therapies. Cancer Manag Res. 2013;5:251–69.

2. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002;99:856–62.

3. Hirt C, Schüler F, Kiefer T, Schwenke C, Haas A, Niederwieser D, et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol. 2008;141:631–40.

4. Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, et al. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol. 2009;27:6094–100.

5. Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009;27:1607–14.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Follow-Up of Patients With Follicular Lymphoma Using Next Generation Sequencing to Detect Minimal Residual Disease;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Minimal residual disease detection in lymphoma: methods, procedures and clinical significance;Frontiers in Immunology;2024-08-12

3. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma;Annals of Oncology;2024-08

4. Progression‐free survival is a weakly predictive surrogate end‐point for overall survival in follicular lymphoma: A systematic review and meta‐analysis;British Journal of Haematology;2024-04-04

5. Tailoring Specific Radiographic Response Criteria for Immunologic Therapies in Lymphoma;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21